LEADER 05459nam 2200673Ia 450 001 9910830161903321 005 20230617035347.0 010 $a1-280-51948-7 010 $a9786610519484 010 $a3-527-60375-1 010 $a3-527-60384-0 035 $a(CKB)1000000000376379 035 $a(EBL)481511 035 $a(OCoLC)69243366 035 $a(SSID)ssj0000211433 035 $a(PQKBManifestationID)11201930 035 $a(PQKBTitleCode)TC0000211433 035 $a(PQKBWorkID)10293010 035 $a(PQKB)11149194 035 $a(MiAaPQ)EBC481511 035 $a(EXLCZ)991000000000376379 100 $a20040716d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNitric oxide donors$b[electronic resource] $efor pharmaceutical and biological applications /$fedited by Peng George Wang, Tingwei Bill Cai, Naoyuki Taniguchi 210 $aWeinheim ;$a[Great Britain] $cWiley-VCH$dc2005 215 $a1 online resource (414 p.) 300 $aDescription based upon print version of record. 311 $a3-527-31015-0 320 $aIncludes bibliographical references and index. 327 $aNitric Oxide Donors; Contents; Preface; List of Contributors; Part 1 Chemistry of NO Donors; 1 NO and NO Donors; 1.1 Introduction to NO Biosynthesis and NO donors; 1.1.1 Nitric Oxide Synthases; 1.1.2 Chemistry of Reactive Nitrogen Species; 1.2 Classification of NO Donors; 1.3 New Classes of NO Donors under Development; 1.3.1 Nitroarene; 1.3.2 Hydroxamic Acids; 1.4 Development of NO-Drug Hybrid Molecules; 1.4.1 Nitrate Hybrid Molecules; 1.4.2 Furoxan Hybrid Molecules; 1.5 New Therapeutic Applications of NO Donors; 1.5.1 NO Donors against Cancer 327 $a1.5.1.1 Diazeniumdiolates (NONOates) as Promising Anticancer Drugs1.5.1.2 The Synergistic Effect of NO and Anticancer Drugs; 1.5.1.3 NO-NSAIDs as a New Generation of Anti-tumoral Agents; 1.5.1.4 Other NO Donors with Anticancer Activity; 1.5.2 NO against Virus; 1.5.2.1 HIV-1 Induces NO Production; 1.5.2.2 Antiviral and Proviral Activity of NO; 1.5.3 Inhibition of Bone Resorption; 1.5.4 Treatment of Diabetes; 1.5.5 Thromboresistant Polymeric Films; 1.5.6 Inhibition of Cysteine Proteases; 1.6 Conclusion; References; 2 Organic Nitrates and Nitrites; 2.1 Organic Nitrates 327 $a2.1.1 Direct Chemical Reaction between Organic Nitrates and Thiols2.1.2 Glutathione-S-transferase; 2.1.3 Cytochrome P-450-dependent Systems; 2.1.4 Membrane-bound Enzyme of Vascular Smooth Muscle Cells; 2.1.5 Xanthine Oxidoreductase; 2.1.6 Mitochondrial Aldehyde Dehydrogenase; 2.1.7 Tolerance; 2.2 Organic Nitrites; 2.3 Conclusions; References; 3 N-Nitroso Compounds; 3.1 Introduction; 3.2 N-Nitrosamines; 3.2.1 Synthesis of Nitrosamines; 3.2.2 Physical Properties and Reactions of N-Nitrosamines; 3.2.3 Structure-Activity Relationship of N-Nitrosamines; 3.2.4 Application of N-Nitrosamines 327 $a3.3 N-Hydroxy-N-nitrosoamines3.3.1 Biologically Active N-Hydroxy-N-nitrosamine Compounds; 3.3.2 Synthesis of N-Hydroxy-N-nitrosamines; 3.3.3 Properties of N-Hydroxy-N-nitrosamines; 3.3.4 Reactivity of N-Hydroxo-N-nitrosamines; 3.4 N-Nitrosimines; 3.4.1 Mechanism of Thermal Reaction of N-Nitrosoimine; 3.4.2 Properties of N-Nitrosoimines; 3.4.3 Synthesis of N-Nitrosoimines; 3.5 N-Diazeniumdiolates; 3.5.1 Mechanism of NO Release; 3.5.2 Synthesis of N-Diazeniumdiolates; 3.5.2.1 Ionic Diazeniumdiolates; 3.5.2.2 O-derivatized Diazeniumdiolates; 3.5.3 Reactions of N-Diazeniumdiolates 327 $a3.5.4 Clinical Applications3.5.4.1 Reversal of Cerebral Vasospasm; 3.5.4.2 Treatment of Impotency; 3.5.4.3 Nonthrombogenic Blood-contact Surfaces; 3.5.5 Future Directions; References; 4 The Role of S-Nitrosothiols in the Biological Milieu; 4.1 Structure and Cellular Reactivity of RSNOs; 4.1.1 RSNO Structure; 4.1.1.1 Enzymatic Consumption of RSNOs; 4.1.2 Formation of RSNOs in the Biological Milieu; 4.1.2.1 Nitrite Mediated; 4.1.2.2 NO Mediated; 4.1.2.3 NO Oxidation Products Mediated; 4.1.2.4 Metalloprotein Mediated; 4.1.2.5 Transnitrosation; 4.2 Postulated Physiological roles of RSNOs 327 $a4.2.1 Regulation of Blood Flow by HbSNO 330 $aNitric oxide is a highly potent regulatory molecule with great pharmaceutical potential. This handbook fills a real gap in combining the chemistry of nitric oxide releasing substances with their practical applications in biology and drug design. It covers all classes of nitric oxide donors, from organic nitrates to nitroso compounds, guanidines and metal-NO complexes.In addition to a detailed treatment of the chemistry of NO donors, numerous examples of successful diagnostic and pharmacological applications are discussed, as well as further therapeutic targets for these substances. 606 $aNitric oxide 606 $aNitric oxide$xPhysiological effect 606 $aDrugs$xDesign 606 $aPharmaceutical chemistry 615 0$aNitric oxide. 615 0$aNitric oxide$xPhysiological effect. 615 0$aDrugs$xDesign. 615 0$aPharmaceutical chemistry. 676 $a572.54 701 $aWang$b Peng George$0738023 701 $aCai$b Tingwai Bill$01611266 701 $aTaniguchi$b Naoyuki$f1942-$01611267 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830161903321 996 $aNitric oxide donors$93939433 997 $aUNINA LEADER 03461nam 22006732 450 001 9910814057403321 005 20151005020623.0 010 $a1-107-23446-8 010 $a1-139-61012-0 010 $a1-139-61198-4 010 $a1-139-62128-9 010 $a1-283-94316-6 010 $a1-139-62500-4 010 $a1-139-60856-8 010 $a1-139-61570-X 010 $a1-139-05179-2 035 $a(CKB)2670000000326610 035 $a(EBL)1099844 035 $a(OCoLC)823724306 035 $a(SSID)ssj0000804561 035 $a(PQKBManifestationID)11431472 035 $a(PQKBTitleCode)TC0000804561 035 $a(PQKBWorkID)10814168 035 $a(PQKB)10709516 035 $a(UkCbUP)CR9781139051798 035 $a(MiAaPQ)EBC1099844 035 $a(Au-PeEL)EBL1099844 035 $a(CaPaEBR)ebr10643430 035 $a(CaONFJC)MIL425566 035 $a(PPN)261276085 035 $a(EXLCZ)992670000000326610 100 $a20110307d2013|||| uy| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe connected self $ethe ethics and governance of the genetic individual /$fHeather Widdows$b[electronic resource] 210 1$aCambridge :$cCambridge University Press,$d2013. 215 $a1 online resource (xiv, 205 pages) $cdigital, PDF file(s) 225 1 $aCambridge bioethics and law 300 $aTitle from publisher's bibliographic system (viewed on 05 Oct 2015). 311 $a1-107-00860-3 320 $aIncludes bibliographical references and index. 327 $aThe individual self and its critics -- The individualist assumptions of bioethical frameworks -- The genetic self is the connected self -- The failures of individual ethics in the genetic era -- The communal turn -- Developing alternatives: benefit sharing -- Developing alternatives: trust -- The ethical toolbox part one: recognising goods and harms -- The ethical toolbox part two: applying appropriate practices -- Possible futures. 330 $aCurrently, the ethics infrastructure - from medical and scientific training to the scrutiny of ethics committees - focuses on trying to reform informed consent to do a job which it is simply not capable of doing. Consent, or choice, is not an effective ethical tool in public ethics and is particularly problematic in the governance of genetics. Heather Widdows suggests using alternative and additional ethical tools and argues that if individuals are to flourish it is necessary to recognise and respect communal and public goods as well as individual goods. To do this she suggests a two-step process - the 'ethical toolbox'. First the harms and goods of the particular situation are assessed and then appropriate practices are put in place to protect goods and prevent harms. This debate speaks to core concerns of contemporary public ethics and suggests a means to identify and prioritise public and common goods. 410 0$aCambridge bioethics and law. 606 $aMedical ethics 606 $aHuman genetics$xResearch$xMoral and ethical aspects 615 0$aMedical ethics. 615 0$aHuman genetics$xResearch$xMoral and ethical aspects. 676 $a174.2/8 700 $aWiddows$b Heather$f1972-$0935821 801 0$bUkCbUP 801 1$bUkCbUP 906 $aBOOK 912 $a9910814057403321 996 $aThe connected self$94070506 997 $aUNINA